Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory
Overlap Syndromes) is an international European-American cooperation providing the framework
for collaborative studies to advance treatment of myelodysplastic/myeloproliferative
neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis
and treatment response.
ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the
ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will
test an active myeloid target compound in combination with ASTX727, an oral drug combining
fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine
deaminase inhibitor E7727, also known as cedazuridine in a single tablet.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Michael Savona
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Incyte Corporation Theradex